Digestive Diseases and Sciences

, Volume 55, Issue 10, pp 2727–2734

Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection

  • Yun-Fan Liaw
  • George K. K. Lau
  • Jia-Horng Kao
  • Edward Gane



Replication of hepatitis B virus (HBV) is the primary driver of disease progression and clinical outcomes in patients with chronic hepatitis B (CHB), but other factors, such as hepatitis B e antigen (HBeAg) status, also influence disease course. The importance of HBeAg seroconversion is underscored by current CHB treatment guidelines that recommend limiting the duration of antiviral therapy in HBeAg-positive patients who achieve seroconversion.


A 2-day meeting of leading hepatologists with extensive experience managing patients with CHB in the Asia–Pacific region was held with the overall goals of reviewing and evaluating (1) available data on the relationship between HBeAg seroconversion and clinical outcomes for patients with HBeAg-positive CHB, and (2) the ways in which seroconversion should influence patient management.


It was agreed that HBeAg seroconversion is an important serologic end point for patients with CHB and that achieving this goal should be an important consideration in treatment selection. Patients with HBeAg-positive CHB should consider pegylated interferon if they are aged <40 years (especially women), have lower HBV DNA levels, can afford this treatment, and have a lifestyle that would support adherence to injection therapy. Alternatively, nucleos(t)ide analogs are recommended in patients with alanine aminotransferase levels ≥2 × the upper limit of normal, HBV DNA levels <9 log10 IU/ml, and compensated CHB. Entecavir, telbivudine, and tenofovir may be used as first-line therapy; they can be administered as a finite therapeutic course in HBeAg-positive patients who seroconvert. Telbivudine and tenofovir should be considered in women of child-bearing potential.


Hepatitis B Hepatitis B e antigen seroconversion Oral nucleos(t)ide therapy Pegylated interferon 


  1. 1.
    Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335–352.CrossRefPubMedGoogle Scholar
  2. 2.
    Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–1527.CrossRefPubMedGoogle Scholar
  3. 3.
    Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–592.CrossRefPubMedGoogle Scholar
  4. 4.
    Ni YH, Chang MH, Chen PJ, et al. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology. 2007;132:2340–2345.CrossRefPubMedGoogle Scholar
  5. 5.
    Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971–975.CrossRefPubMedGoogle Scholar
  6. 6.
    Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg-positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46:45–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422–1427.CrossRefPubMedGoogle Scholar
  8. 8.
    van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology. 2004;39:804–810.CrossRefPubMedGoogle Scholar
  9. 9.
    Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686.CrossRefPubMedGoogle Scholar
  11. 11.
    Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921–931.CrossRefPubMedGoogle Scholar
  12. 12.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–242.CrossRefGoogle Scholar
  13. 13.
    Liaw Y-F, Leung N, Kao J-H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–283.CrossRefPubMedGoogle Scholar
  14. 14.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.CrossRefPubMedGoogle Scholar
  15. 15.
    Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315–1341.CrossRefPubMedGoogle Scholar
  16. 16.
    Liaw Y-F. Antiviral therapies of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol. 2009;51:403–410.CrossRefPubMedGoogle Scholar
  17. 17.
    Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254–265.CrossRefPubMedGoogle Scholar
  18. 18.
    Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med. 2007;147:58–61.PubMedGoogle Scholar
  19. 19.
    Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–174.CrossRefPubMedGoogle Scholar
  20. 20.
    Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29(suppl 1):100–107.CrossRefPubMedGoogle Scholar
  21. 21.
    Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol. 2003;18:246–252.CrossRefPubMedGoogle Scholar
  22. 22.
    Ratnam D, Visvanathan K. New concepts in the immunopathogenesis of chronic hepatitis B: the importance of the innate immune response. Hepatol Int. 2008;2(suppl 1):12–18.CrossRefPubMedGoogle Scholar
  23. 23.
    Wang FS, Zhang Z. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Rev Gastroenterol Hepatol. 2009;3:499–512.CrossRefPubMedGoogle Scholar
  24. 24.
    Bortolotti F, Guido M, Bartolacci S, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology. 2006;43:556–562.CrossRefPubMedGoogle Scholar
  25. 25.
    Hui CK, Leung N, Shek TW, et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology. 2007;46:690–698.CrossRefPubMedGoogle Scholar
  26. 26.
    Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology. 2007;133:1458–1465.CrossRefPubMedGoogle Scholar
  27. 27.
    Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829–834.CrossRefPubMedGoogle Scholar
  28. 28.
    Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat. 2007;14:147–152.CrossRefPubMedGoogle Scholar
  29. 29.
    Liaw Y-F. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int. 2009;3:425–433.CrossRefGoogle Scholar
  30. 30.
    Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int. 2007;1:415–430.CrossRefPubMedGoogle Scholar
  31. 31.
    Sanchez-Tapias JM, Costa J, Mas A, Pares A, Bruguera M, Rodes J. Analysis of factors predicting early seroconversion to anti-HBe in HBeAg-positive chronic hepatitis B. J Hepatol. 1988;6:15–22.CrossRefPubMedGoogle Scholar
  32. 32.
    Yuen MF, Wong DK, Sablon E, et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther. 2003;8:531–534.PubMedGoogle Scholar
  33. 33.
    Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122:1756–1762.CrossRefPubMedGoogle Scholar
  34. 34.
    Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol. 2005;43:411–417.CrossRefPubMedGoogle Scholar
  35. 35.
    Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol. 2004;72:363–369.CrossRefPubMedGoogle Scholar
  36. 36.
    Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology. 2007;133:1452–1457.CrossRefPubMedGoogle Scholar
  37. 37.
    Yuen MF, Wong DK, Zheng BJ, et al. Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion. J Viral Hepat. 2007;14:269–275.CrossRefPubMedGoogle Scholar
  38. 38.
    Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45:1187–1192.CrossRefPubMedGoogle Scholar
  39. 39.
    Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084–1089.CrossRefPubMedGoogle Scholar
  40. 40.
    Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther. 2010. doi:10.3851/IMP1497.
  41. 41.
    Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–1010.CrossRefPubMedGoogle Scholar
  42. 42.
    Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123–129.CrossRefPubMedGoogle Scholar
  43. 43.
    Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–2588.CrossRefPubMedGoogle Scholar
  44. 44.
    Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–2695.CrossRefPubMedGoogle Scholar
  45. 45.
    Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808–816.CrossRefPubMedGoogle Scholar
  46. 46.
    Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.CrossRefPubMedGoogle Scholar
  47. 47.
    Piratvisuth T, Lau G, Chao Y. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int. 2008;2:102–110.CrossRefPubMedGoogle Scholar
  48. 48.
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000;32:803–806.CrossRefPubMedGoogle Scholar
  49. 49.
    Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48:750–758.CrossRefPubMedGoogle Scholar
  50. 50.
    Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133:1437–1444.CrossRefPubMedGoogle Scholar
  51. 51.
    Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422–430.PubMedGoogle Scholar
  52. 52.
    Heathcote JE, Gane E, deMan R. Two-year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103) (abstract no. 158). Hepatology. 2008;48(suppl 1):376A.Google Scholar
  53. 53.
    Heathcote EJ, Gane E, De Man RA, et al. Three years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg +) with chronic hepatitis B (Study 103). Hepatology. 2009;50:533A–534A.Google Scholar
  54. 54.
    Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–495.CrossRefPubMedGoogle Scholar
  55. 55.
    Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47:447–454.CrossRefPubMedGoogle Scholar
  56. 56.
    Jia JD, Hou JL, Yin YK, et al. Two-year results of a phase III comparative trial of telbivudine vs. lamivudine in Chinese patients (abstract no. 497). J Hepatol. 2007;46:S189.CrossRefGoogle Scholar
  57. 57.
    Hsu CW, Chen YC, Liaw YF, et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from globe and 015 studies in chronic hepatitis B patients (abstract no. 911). J Hepatol. 2009;50:S331.CrossRefGoogle Scholar
  58. 58.
    Jia J, Hou J, Yin Y, et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in Chinese chronic hepatitis B (abstract no. FP034). Hepatol Int. 2009;2(suppl 1):43–44.Google Scholar
  59. 59.
    Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 2009;51:11–20.CrossRefPubMedGoogle Scholar
  60. 60.
    Evans A, Riva A, Cooksley H, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatology. 2008;48:759–769.CrossRefPubMedGoogle Scholar
  61. 61.
    Wu Z, Yan W, Guo W, et al. Telbivudine preserves Th1 cytokine and inhibits Th2 cytokine production in MHV-3 induced viral hepatitis model. J Viral Hepat. 2010;17(suppl 1):1–10.Google Scholar
  62. 62.
    Yuan HJ, Ka-Ho WD, Doutreloigne J, Sablon E, Lai CL, Yuen MF. Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. J Infect. 2007;54:497–503.CrossRefPubMedGoogle Scholar
  63. 63.
    Lee HC, Suh DJ, Ryu SH, et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut. 2003;52:1779–1783.CrossRefPubMedGoogle Scholar
  64. 64.
    Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat. 2002;9:208–212.CrossRefPubMedGoogle Scholar
  65. 65.
    Yoon SK, Jang JW, Kim CW, et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology. 2005;48:341–349.CrossRefPubMedGoogle Scholar
  66. 66.
    van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut. 2003;52:420–424.CrossRefPubMedGoogle Scholar
  67. 67.
    Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003;38:1267–1273.CrossRefPubMedGoogle Scholar
  68. 68.
    Degertekin B, Lok AS. Update on viral hepatitis: 2008. Curr Opin Gastroenterol. 2009;25:180–185.CrossRefPubMedGoogle Scholar
  69. 69.
    Ryu SH, Chung YH, Choi MH, et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol. 2003;39:614–619.CrossRefPubMedGoogle Scholar
  70. 70.
    Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol Int. 2008;2:284–295.CrossRefPubMedGoogle Scholar
  71. 71.
    Yang BM, Paik SW, Hahn OS, Yi DH, Choi MS, Payne S. Economic evaluation of the societal costs of hepatitis B in South Korea. J Gastroenterol Hepatol. 2001;16:301–308.CrossRefPubMedGoogle Scholar
  72. 72.
    Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137:2002–2009.CrossRefPubMedGoogle Scholar
  73. 73.
    ACT-HBV Asia-Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int. 2006;26:47–58.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Yun-Fan Liaw
    • 1
  • George K. K. Lau
    • 2
  • Jia-Horng Kao
    • 3
  • Edward Gane
    • 4
  1. 1.Liver Research UnitChang Gung Memorial Hospital and Chang Gung University College of MedicineTaipeiTaiwan
  2. 2.Clinical Trial Center, LKS Faculty of MedicineThe University of Hong Kong, Humanity and Health GI and Liver ClinicHong KongChina
  3. 3.Hepatitis Research Center National Taiwan University HospitalTaipeiTaiwan
  4. 4.New Zealand Liver Transplant UnitAuckland City HospitalAucklandNew Zealand

Personalised recommendations